Literature DB >> 2283516

Intranasal apomorphine: a new treatment in Parkinson's disease.

R Kapoor, N Turjanski, J Frankel, B Kleedorfer, A Lees, G Stern, M Bovingdon, R Webster.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2283516      PMCID： PMC488291          DOI： 10.1136/jnnp.53.11.1015

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  1 in total

1.  Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease.

Authors:  P A Kempster; J P Frankel; M Bovingdon; R Webster; A J Lees; G M Stern
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154
  1 in total
  12 in total

Review 1.  Pharmacological treatment of Parkinson's disease.

Authors:  A Münchau; K P Bhatia
Journal:  Postgrad Med J       Date:  2000-10       Impact factor: 2.401

2.  Paradoxical akinetic response to apomorphine in parkinsonism.

Authors:  J R Jenkins; J M Pearce
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-05       Impact factor: 10.154

Review 3.  Old Drugs, New Delivery Systems in Parkinson's Disease.

Authors:  Harsh V Gupta; Kelly E Lyons; Rajesh Pahwa
Journal:  Drugs Aging       Date:  2019-09       Impact factor: 3.923

4.  Iontophoretic delivery of apomorphine. II: An in vivo study in patients with Parkinson's disease.

Authors:  R van der Geest; T van Laar; J M Gubbens-Stibbe; H E Boddé; M Danhof
Journal:  Pharm Res       Date:  1997-12       Impact factor: 4.200

Review 5.  Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.

Authors:  Dirk Deleu; Margaret G Northway; Yolande Hanssens
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 6.  Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease.

Authors:  C Neef; T van Laar
Journal:  Clin Pharmacokinet       Date:  1999-09       Impact factor: 6.447

Review 7.  Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia.

Authors:  Amy F T Arnsten; Ragy R Girgis; David L Gray; Richard B Mailman
Journal:  Biol Psychiatry       Date:  2016-01-18       Impact factor: 13.382

8.  Apomorphine pharmacokinetics in parkinsonism after intranasal and subcutaneous application.

Authors:  E Sam; A P Jeanjean; J M Maloteaux; N Verbeke
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1995 Jan-Mar       Impact factor: 2.441

9.  Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study.

Authors:  L Ostergaard; L Werdelin; P Odin; O Lindvall; E Dupont; P B Christensen; E Boisen; N B Jensen; S H Ingwersen; M Schmiegelow
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-06       Impact factor: 10.154

10.  Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up.

Authors:  K Pietz; P Hagell; P Odin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-11       Impact factor: 10.154
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.